Loading...

Gossamer Bio

DB:4GB
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4GB
DB
$966M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Gossamer Bio has significant price volatility in the past 3 months.
4GB Share Price and Events
7 Day Returns
-4.8%
DB:4GB
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:4GB
-10.2%
DE Biotechs
-6%
DE Market
4GB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Gossamer Bio (4GB) -4.8% -29.1% - - - -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 4GB.
  • No trading data on 4GB.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Gossamer Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Gossamer Bio is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Gossamer Bio has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Gossamer Bio. This is due to cash flow or dividend data being unavailable. The share price is €14.202.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Gossamer Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Gossamer Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4GB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-22.59
NasdaqGS:GOSS Share Price ** NasdaqGS (2019-04-18) in USD $16.54
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Gossamer Bio.

DB:4GB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:GOSS Share Price ÷ EPS (both in USD)

= 16.54 ÷ -22.59

-0.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gossamer Bio is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Gossamer Bio is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Gossamer Bio's expected growth come at a high price?
Raw Data
DB:4GB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-11.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Gossamer Bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Gossamer Bio's assets?
Raw Data
DB:4GB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-14.91
NasdaqGS:GOSS Share Price * NasdaqGS (2019-04-18) in USD $16.54
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:4GB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:GOSS Share Price ÷ Book Value per Share (both in USD)

= 16.54 ÷ -14.91

-1.11x

* Primary Listing of Gossamer Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gossamer Bio has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Examine Gossamer Bio's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Gossamer Bio's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Gossamer Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Gossamer Bio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Gossamer Bio expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-11.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Gossamer Bio expected to grow at an attractive rate?
  • Unable to compare Gossamer Bio's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Gossamer Bio's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Gossamer Bio's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:4GB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4GB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -11.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4GB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4GB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 99 -235 -238 2
2022-12-31 0 -293 -355 2
2021-12-31 0 -267 -328 2
2020-12-31 0 -217 -343 2
2019-12-31 0 -177 -267 2
DB:4GB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -51 -147
2018-09-30 -32 -115
2018-06-30 -16 -66
2018-03-31 -11 -36
2017-12-31 -6 -7
2016-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Gossamer Bio is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Gossamer Bio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4GB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Gossamer Bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4GB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.54 -2.54 -2.54 1.00
2022-12-31 -3.99 -3.99 -3.99 1.00
2021-12-31 -3.88 -3.88 -3.88 1.00
2020-12-31 -4.50 -3.57 -5.42 2.00
2019-12-31 -4.06 -4.06 -4.06 1.00
DB:4GB Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -22.59
2018-09-30 -16.64
2018-06-30 -8.65
2018-03-31 -4.32
2017-12-31 -0.74
2016-12-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Gossamer Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Gossamer Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Gossamer Bio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Gossamer Bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Gossamer Bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Gossamer Bio does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Gossamer Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Gossamer Bio's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Gossamer Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Gossamer Bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4GB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -146.97 44.05 55.28
2018-09-30 -114.63 30.27 30.09
2018-06-30 -65.51 7.44 11.44
2018-03-31 -36.14 3.85 6.17
2017-12-31 -6.77 0.26 0.89
2016-12-31 -0.08 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Gossamer Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Gossamer Bio has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Gossamer Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Gossamer Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Gossamer Bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Gossamer Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Gossamer Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Gossamer Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Gossamer Bio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Gossamer Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Gossamer Bio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Gossamer Bio Company Filings, last reported 3 months ago.

DB:4GB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 218.30 0.00 228.66
2018-09-30 246.59 0.00 256.44
2018-06-30 48.04 0.00 52.15
2018-03-31 48.04 0.00 52.15
2017-12-31 -6.86 6.04 0.32
2016-12-31 -0.12 0.04 0.06
  • Gossamer Bio has no debt.
  • Gossamer Bio currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Gossamer Bio has sufficient cash runway for more than 3 years based on current free cash flow.
  • Gossamer Bio has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 118.6% each year.
X
Financial health checks
We assess Gossamer Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Gossamer Bio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Gossamer Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Gossamer Bio dividends. Estimated to be 0% next year.
If you bought €2,000 of Gossamer Bio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Gossamer Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Gossamer Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4GB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4GB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Gossamer Bio has not reported any payouts.
  • Unable to verify if Gossamer Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Gossamer Bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Gossamer Bio has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Gossamer Bio's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Gossamer Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Gossamer Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Gossamer Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Gossamer Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sheila Gujrathi
COMPENSATION $18,412,212
AGE 48
TENURE AS CEO 0.8 years
CEO Bio

Dr. Sheila K. Gujrathi, M.D., is the Co-Founder and President of Gossamer Bio, Inc. since October 2015 and has been its Chief Executive Officer since July 23, 2018. Dr. Gujrathi has been a Director of Gossamer Bio, Inc. since October 2015. She has been Chairman of the board at Turning Point Therapeutics, Inc. since April 2019 and has been its Director since November 2017. Dr. Gujrathi served as Chief operating Officer of Gossamer Bio, Inc. from October 2015 to July 23, 2018. She has been Strategic Advisor at TP Therapeutics, Inc. since December 2017. Dr. Gujrathi has extensive development, clinical and executive management experience. From 1999 to 2002, Dr. Gujrathi was Management Consultant in McKinsey & Company's healthcare practice. She serves as a Member of Advisory Board of BioXcel Therapeutics, Inc. She served as the Chief Medical officer of Receptos, Inc. from June 2011 to August 27, 2015. She led expansion of development activities for both the S1P1 agonist portfolio and additional assets in the immunology therapeutic area at Receptos, Inc. She joined Receptos from Bristol-Myers Squibb (BMS), where she served as a Vice President of the Global Clinical Development Group in Immunology from 2008 to 2011. She was responsible for late-stage clinical development for Orencia(R), Nulojix(R), and other clinical immunology assets being developed in rheumatoid arthritis (RA), solid organ transplant, systemic lupus erythematosus, juvenile idiopathic arthritis (JIA), and inflammatory bowel disease. Dr. Gujrathi was at Genentech from 2002 to 2008 where she held roles of increasing responsibility in the immunology, tissue growth and repair clinical development group and served as the Avastin franchise team leader. Dr. Gujrathi was instrumental in preparing several regulatory submissions in the US, EU and other countries for Orencia(R) IV and SC sBLA applications in RA and JIA, as well as for Nulojix(R) in kidney transplant recipients, which included a positive FDA advisory committee hearing. In addition, she provided strategic direction and leadership for the Immunoscience franchise at BMS, including external business development opportunities, where she was involved in acquisitions of several immunology compounds both in the discovery and clinical stages of development. She has wealth of knowledge and clinical development experience in immunology to in-license additional programs for preclinical and clinical development pipeline. She has been a Director of TP Therapeutics, Inc. since December 2017. She has been a Director of Five Prime Therapeutics, Inc., since December 2, 2015. She served as a Director of Ambrx, Inc. since February 24, 2014. She was named amongst “50 Female Entrepreneurs Everyone Should Know” in March 2019. Dr. Gujrathi holds a Bachelor of Science in Biomedical Engineering and a Doctor of Medicine from Northwestern University in the accelerated Honors Program in Medical Education. She completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and additional fellowship training in Allergy/Immunology at UCSF and Stanford University in their Allergy and Immunology Fellowship Program.

CEO Compensation
  • Insufficient data for Sheila to compare compensation growth.
  • Sheila's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Gossamer Bio management team in years:

0.8
Average Tenure
52
Average Age
  • The average tenure for the Gossamer Bio management team is less than 2 years, this suggests a new team.
Management Team

Faheem Hasnain

TITLE
Co-Founder & Executive Chairman
COMPENSATION
$18M
AGE
60

Sheila Gujrathi

TITLE
Co-Founder
COMPENSATION
$18M
AGE
48
TENURE
0.8 yrs

Bryan Giraudo

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
42
TENURE
0.9 yrs

Christian Waage

TITLE
Executive VP
COMPENSATION
$682K
AGE
51
TENURE
1.7 yrs

Jakob Dupont

TITLE
Chief Medical Officer
COMPENSATION
$4M
AGE
53
TENURE
0.3 yrs

Luisa Salter-Cid

TITLE
Chief Scientific Officer
AGE
58
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Gossamer Bio board of directors in years:

1.3
Average Tenure
47
Average Age
  • The average tenure for the Gossamer Bio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Sheila Gujrathi

TITLE
Co-Founder
COMPENSATION
$18M
AGE
48
TENURE
3.5 yrs

Kristina Burow

TITLE
Director
AGE
45
TENURE
1.3 yrs

Faheem Hasnain

TITLE
Co-Founder & Executive Chairman
COMPENSATION
$18M
AGE
60
TENURE
3.5 yrs

Renée Galá

TITLE
Director
COMPENSATION
$332K
AGE
45
TENURE
0.3 yrs

Otello Stampacchia

TITLE
Director
AGE
44
TENURE
1.3 yrs

Josh Bilenker

TITLE
Director
COMPENSATION
$332K
AGE
46
TENURE
0.3 yrs

Russ Cox

TITLE
Director
COMPENSATION
$332K
AGE
55
TENURE
0.4 yrs

Tom Daniel

TITLE
Director
COMPENSATION
$224K
AGE
64
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Gossamer Bio insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Feb 19 Buy Christian Waage Individual 12. Feb 19 12. Feb 19 1,550 €14.14 €21,916
12. Feb 19 Buy Bryan Giraudo Individual 12. Feb 19 12. Feb 19 6,000 €14.14 €84,835
12. Feb 19 Buy Russell Cox Individual 12. Feb 19 12. Feb 19 7,200 €14.14 €101,802
X
Management checks
We assess Gossamer Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Gossamer Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.

Details
Name: Gossamer Bio, Inc.
4GB
Exchange: DB
Founded: 2015
$857,848,703
58,393,489
Website: http://www.gossamerbio.com
Address: Gossamer Bio, Inc.
3013 Science Park Road,
Suite 200,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS GOSS Common Stock Nasdaq Global Select US USD 08. Feb 2019
DB 4GB Common Stock Deutsche Boerse AG DE EUR 08. Feb 2019
MUN 4GB Common Stock Boerse Muenchen DE EUR 08. Feb 2019
Number of employees
Current staff
Staff numbers
119
Gossamer Bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:59
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.